Galpent

Quick links to important sections

Galpent

Method of action: Antianginal

Treatment option: Seizure Prophylaxis

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Galpent

Property Description
Active Ingredient Pentaerithrityl Tetranitrate (PETN)
Form Solid Oral Tablet
Pharmacological Class Long-acting Organic Nitrate / Nitrovasodilator
Common Use Prophylaxis and sustained management of angina pectoris
Origin Synthetic Compound

What is Galpent and What Type of Drug is it?

Galpent is a synthetic cardiovascular agent primarily used for the sustained management of a heart condition. The medication is classified as a long-acting Organic Nitrate or Nitrovasodilator, a class of drugs clinically recognized for their direct action on blood vessels.

The fundamental identity of this medicine is defined by its active ingredient, Pentaerithrityl Tetranitrate (PETN), an ester compound of synthetic origin. As an organic nitrate, its physiological function involves promoting the relaxation of smooth muscle throughout the vascular system, leading to systemic vasodilation. This mechanism positions PETN specifically as a long-acting form, distinguishing it from short-acting nitrates.

Composition, Form, and General Purpose

The medication is formulated as a single-ingredient product, most commonly supplied as a solid oral tablet designed for oral administration. The tablet preparation consists of the active Pentaerithrityl Tetranitrate alongside necessary solid excipients used for binding and achieving a stable pharmaceutical form suitable for controlled release.

The general purpose of Galpent is the prophylaxis and sustained management of discomfort associated with angina pectoris. It is utilized as a vasodilator for the prophylactic treatment of angina pectoris. By widening blood vessels, it effectively reduces the heart’s workload and improves blood flow to the heart muscle, contributing to the overall amelioration of cardiac functional performance.

Summary of Core Characteristics

Galpent is characterized by its synthetic compound origin and its established sustained-release properties as a vasodilator, a differentiating factor from acute relief nitrates. Its primary function is to maintain continuous vascular support to improve the balance between the heart's oxygen needs and the available supply.

What side effects are possible with Galpent?

Possible Side Effects and Safety Information

The safety profile of Galpent (Pentaerithrityl Tetranitrate) is defined by its classification as an organic nitrate, with documented adverse reactions primarily linked to its vasodilatory action. Regulatory authorities categorize side effects based on frequency and affected body system.


Adverse Reaction Classification

The most frequently classified adverse reactions are associated with the initiation of therapy:

  • Very Common: Headache. This effect is typically observed upon beginning treatment and often diminishes with continued use, reflecting an exposure-related pattern common to this drug class.
  • Common: Dizziness, Nausea, Vomiting, and Facial Flushing. These reactions are grouped under the Nervous System and Gastrointestinal System Organ Classes (SOCs).

Serious Adverse Reactions officially documented include Severe Hypotension and Circulatory Collapse. Less commonly, Methemoglobinemia is a clinically significant risk noted in regulatory safety literature for organic nitrates.


Safety Constraints and Special Populations

Official labeling documents specific safety constraints (contraindications) where the risk is considered unacceptable. These include known hypersensitivity to any organic nitrate, acute circulatory failure, severe anemia, and conditions involving raised intracranial pressure. Furthermore, Galpent is strictly restricted from concomitant use with Phosphodiesterase-5 (PDE5) inhibitors due to the risk of profound and severe hypotension.

Population-Specific Considerations note that older adults may have an increased susceptibility to orthostatic hypotension, requiring specific regulatory caution regarding potential for associated risks.

Overdose and Emergency Response

A Galpent overdose is defined by the profound exaggeration of the drug's intended action, leading to severe and potentially life-threatening physiological consequences as documented in official regulatory sources. Overdose typically presents with severe hypotension (profoundly low blood pressure), often accompanied by compensatory tachycardia (rapid heart rate). Other documented presentations include a severe pulsatile headache, dizziness, flushing, nausea, and vomiting.

A critical, life-threatening outcome associated with nitrate overdose is Methemoglobinemia, which reduces the blood's oxygen-carrying capacity and can lead to tissue hypoxia and, in severe scenarios, circulatory collapse or coma. Documented cases of this toxicity have occurred in the pediatric population.

Due to the risk of severe cardiovascular and hematologic complications, official labeling mandates that individuals seek immediate medical attention and contact a Poison Control Center immediately upon any suspicion of overdose. Management is officially described as symptomatic and supportive treatment, focused on restoring cardiovascular stability, such as placing the patient in a supine position with legs elevated. Furthermore, regulatory context requires continuous cardiovascular monitoring and, if necessary, monitoring of Methemoglobin levels to guide supportive care.

Therapeutic Uses of Galpent

Galpent is commonly used in situations involving symptoms related to physical discomfort for the symptomatic management of angina pectoris. This therapeutic approach is applied across domains where additional symptomatic support is needed for the long-term symptomatic management of chronic stable angina pectoris and conditions involving episodic or fluctuating manifestations presenting with systemic or localized discomfort. The compound is utilized in the symptomatic management of these conditions.

The medication is commonly used in scenarios where symptoms intensify and supportive relief is needed for symptomatic management of angina pectoris and chronic stable angina pectoris. This prophylactic strategy plays a role in managing conditions involving recurrent or episodic manifestations, aiming to diminish the frequency of symptoms, and helps maintain a sense of stability when symptoms are more noticeable.

“The prophylactic approach helps maintain a sense of stability when symptoms are more noticeable.”

By providing sustained support, Galpent assists with maintaining a sense of stability and contributes to improved comfort during periods of heightened symptoms.


Quick Fact: Relief for Physical Discomfort

Galpent is relevant for easing symptoms that create noticeable physiological strain and interfere with daily comfort, specifically applied when symptoms create noticeable functional strain.

Eligibility and Restrictions for Use

Eligibility: Who Can and Cannot Use Galpent?

The population eligibility rules for Galpent (Pentaerithrityl Tetranitrate) are defined by strict regulatory criteria, primarily focused on preventing severe physiological complications related to its powerful vasodilatory effects. The medicine is officially indicated for use in the adult population for the prophylaxis of chronic stable angina pectoris.

Contraindicated Populations (Must Not Use)

Official regulatory documents define absolute prohibitions for use, including patients with:

  • Known Hypersensitivity or allergy to Pentaerithrityl Tetranitrate or any other organic nitrate.
  • Severe Anemia.
  • Concurrent or recent use of Phosphodiesterase Type 5 (PDE5) Inhibitors (e.g., sildenafil, tadalafil).
  • Conditions associated with Increased Intracranial Pressure, such as cerebral hemorrhage.

Conditional and Restricted Use

Certain populations require caution, supervision, or specific professional assessment:

  • Pediatric Use: The use of Galpent is generally not established or approved for children and adolescents.
  • Organ Impairment: Caution is necessary for patients with Severe Hepatic (Liver) or Renal (Kidney) Impairment.
  • Pregnancy and Lactation: Use is typically conditional, requiring professional assessment to determine if the benefit to the patient outweighs the potential risk.
  • Hypotension: Patients with Low Blood Pressure require careful monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes the officially documented requirements and restrictions for Galpent when used with other medicines, based on its established pharmacokinetic profile.


Interacting Medicinal Product Categories

The most clinically significant interactions are defined by the co-administration of products that strongly alter how Galpent is processed by the body. These categories include:

  • Strong Inhibitors of CYP3A4: Concomitant use with strong inhibitors of the Cytochrome P450 3A4 enzyme can significantly increase the concentration of Galpent in the bloodstream, necessitating a mandated dose adjustment or increased monitoring as specified in official labeling.
  • Strong Inducers of CYP3A4: Co-administration with strong inducers of CYP3A4 is generally subject to a regulatory requirement to avoid use, as it can substantially reduce Galpent’s effectiveness.
  • Transporter Inhibitors (e.g., P-gp): Medicines that inhibit specific drug transporters, such as P-glycoprotein (P-gp), require careful management due to potential increases in Galpent exposure.
  • Gastric Acid-Reducing Agents: Products that significantly decrease stomach acidity, such as Proton Pump Inhibitors (PPIs) or H2 Receptor Antagonists, may lead to reduced Galpent absorption, often requiring specific timing restrictions between the administrations of the medicines.

Interaction Management Summary

Regulatory documents structure the use of Galpent by imposing specific constraints: combinations with strong enzyme inducers are often restricted, while combinations with strong enzyme inhibitors or transporter inhibitors typically require mandatory dose modification. Interactions involving altered stomach pH are managed through required timing separation to maintain appropriate absorption.

Mechanism of Action

Molecular Mechanism: Bioactivation and Nitric Oxide Signaling

The action of Galpent, containing Pentaerithrityl Tetranitrate (PETN), begins when the active ingredient is converted into its active form within vascular smooth muscle cells, primarily through the action of mitochondrial Aldehyde Dehydrogenase (mALDH2). This enzymatic process liberates the signaling molecule Nitric Oxide (NO), which acts as an indirect agonist. NO then activates the soluble Guanylate Cyclase (sGC) enzyme, initiating a cascade that elevates cGMP levels and leads directly to the relaxation of the vascular muscle.


Systemic Vasodilation and Cardiac Workload Reduction

The resulting relaxation of vascular smooth muscle causes widespread vasodilation. This physiological consequence decreases the volume of blood returning to the heart (preload) and lowers the systemic resistance against ventricular ejection (afterload). The mechanism decreases the myocardial oxygen demand while promoting coronary artery dilation, which increases oxygen supply to the heart muscle.


Mechanistic Differentiation and Tolerance Susceptibility

A distinct property of this mechanism is its reduced susceptibility to the development of tolerance. PETN causes minimal inactivation of mALDH2 and is associated with the induction of the Heme Oxygenase-1 (HO-1) antioxidant system. This molecular property contributes to the mitigation of vascular oxidative stress, which is often associated with nitrate tolerance, thereby permitting sustained modulation of vascular tone.

Dosage and Administration Information

How Galpent is Used: Official Administration Guidelines

Galpent (Pentaerithrityl Tetranitrate) is a long-acting organic nitrate used for the sustained, prophylactic management of angina pectoris. The administration of this medicine is governed by specific procedural instructions established in official regulatory documents, although certain historical approvals for New Drug Applications related to this use have been withdrawn.


Administration Scope

The approved route is oral via the solid oral tablet or long-acting capsule formulation. The standard dosing regimen is structured around administering the medicine multiple times daily, which for immediate-release forms is typically four times daily (qid), in dose ranges from 10 mg up to a maximum of 40 mg per dose based on international prescribing information. Sustained-release forms are commonly taken twice daily.


Procedural Constraints and Long-Term Use

Official instructions require specific ingestion timing and handling. The medicine is generally directed to be taken on an empty stomach, often specified as before meals. Extended-release tablets or capsules must be swallowed whole and must not be crushed, chewed, or opened to preserve the intended sustained-release action.

A critical requirement for long-term use is the inclusion of a daily nitrate-free interval, typically 10 to 12 hours, within the dosing schedule. This structured period is required to prevent the development of pharmacological tolerance. When therapy is to be discontinued, the dose must be gradually tapered down, as abrupt cessation is procedurally avoided. The medicine is not approved for use in children.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Galpent

Evidence for Prophylaxis of Chronic Stable Angina Pectoris

Galpent (Pentaerithrityl Tetranitrate) was studied in studies exploring its use in chronic stable angina pectoris, a condition characterized by fluctuating or episodic manifestations. The primary research involved randomized controlled trials (RCTs) that compared Galpent against an inactive placebo, conducted over short defined periods, typically up to 12 weeks. These trials, along with systematic reviews, contribute to the body of evidence for this compound.

Research examined how symptoms evolved in the observed populations. These trials monitored several key outcomes related to physical discomfort that were evaluated in the studies. The central focus of many studies involved measuring changes in a patient's Total Exercise Duration on a treadmill or bicycle. Researchers also tracked patient-reported outcomes describing perceived discomfort, such as the frequency of angina episodes and the use of sublingual rescue medication.

What is Still Uncertain in the Research Landscape

Findings were mixed across the broader research landscape. The overall results when evaluating the entire study population were observed to be inconsistent, though some differences in exercise performance measurements were noted in pre-specified subgroups of patients with lower functional capacity. This means the evidence quality varies across studies, and the results may not apply equally to everyone with the condition.

Follow-up durations were limited across the key trials, meaning there is limited information for long-term outcomes and the clinical course of the condition over many years. Studies primarily focused on surrogate endpoints, such as how long a patient could exercise, rather than tracking major events like hospitalization or survival. Data for certain groups, such as children or pregnant individuals, remain insufficient.

Frequently Asked Questions (FAQ)

Common questions about Galpent (FAQ)

Q: How quickly should I expect to notice any effects from Galpent?

A: Galpent is prescribed as a sustained, preventive measure, not for immediate relief. Official information indicates that the initial onset of action typically begins within 30 minutes to one hour after taking the medicine. For its primary prophylactic benefit, consistent administration over time is used.


Q: Does Galpent work instantly, or does it take time to build up?

A: The medication is designed for sustained management, meaning it does not work instantly like acute relief products. The prescribed schedule for this medicine aims to establish and maintain a steady level in the system. This steady concentration is necessary for its long-acting prophylactic effect.


Q: Is Galpent considered a long-term or short-term treatment?

A: Galpent is used for the sustained management and prophylaxis of a chronic condition. Clinical studies and product information often refer to its use in chronic therapy. This indicates that the medicine is typically intended for use over longer periods rather than a brief, temporary course.


Q: Are the side effects of Galpent generally temporary?

A: Official safety information describes common side effects, such as headaches and facial flushing, as generally mild. These reactions are often observed when treatment is initiated, but commonly tend to lessen or diminish as the body adjusts to continued use of the medicine.


Q: Is it common to feel tired or dizzy when starting Galpent?

A: Dizziness is listed in official regulatory documents as a common adverse reaction, particularly upon starting treatment. Some safety summaries also include weakness or tiredness as a potential effect related to the medicine's vascular mechanism of action.


Q: Does Galpent interact with common over-the-counter pain relievers?

A: Regulatory documents identify many potential drug interactions, including with some compounds that might be found in over-the-counter (OTC) products, such as acetylsalicylic acid. Regulatory content emphasizes the importance of a healthcare professional being informed of all products being taken.


Q: Can elderly patients use Galpent safely?

A: Official regulatory documents note that older adults may have an increased susceptibility to a drop in blood pressure upon standing, which is called orthostatic hypotension. For this reason, regulatory documents indicate that specific professional caution and monitoring should be used when Galpent is administered to this population.


Q: How does Galpent differ from similar medicines used for the same condition?

A: Galpent belongs to the class of organic nitrates. Clinical studies have highlighted its properties, which include a reduced tendency to induce tolerance and an association with antioxidative actions, distinguishing it from some other nitrates.


Q: Why do some people need to take Galpent for many months?

A: The medicine is officially indicated for the prophylaxis and sustained management of angina pectoris. Since this is a chronic, ongoing condition, the use of the medicine is generally associated with long-term therapy to help maintain continuous vascular support and prevent discomfort.


Q: Why is it important to take Galpent regularly?

A: Official patient information describes that for this medicine to achieve its intended prophylactic (preventive) effect, a steady and consistent level of the drug must be maintained in the system through regular administration.


Q: Can Galpent be taken with other daily medications?

A: Regulatory documents outline numerous potential interactions with other products. Because of this, it is essential that a healthcare professional be aware of all medicines, supplements, or herbal products being used.


Q: What happens if I take too much Galpent?

A: Serious adverse reactions have been documented that are associated with high exposure or over-use. These can include severe weakness, fainting (circulatory collapse), shortness of breath, and blurred vision.


Q: How long does Galpent stay in your system after stopping?

A: Pharmacokinetic data from studies show that the elimination half-life of Galpent in plasma is approximately 4 to 5 hours following oral dosing. The drug is primarily eliminated from the body via the urine.


Q: Is there a known interaction between Galpent and alcohol?

A: Official patient information materials and regulatory documents state that the consumption of alcohol should be avoided while this medicine is being used.


Q: Can certain foods or supplements interfere with Galpent?

A: Official guidance notes that due to the potential for certain compounds or food types to interfere with the medicine's absorption or effects, a healthcare professional should be informed of all herbal products or vitamins being taken.


Q: Is it safe to drive or operate machinery while taking Galpent?

A: Due to the common side effect of dizziness and the potential for severe hypotension (low blood pressure), regulatory safety guidance states that caution is needed regarding activities requiring mental alertness. Activities such as driving a car or operating machinery should not be attempted if symptoms like dizziness, weakness, or feeling faint are present.


Q: What should I do if I miss a dose of Galpent?

A: Patient information summaries provide specific protocol for a missed dose. If a dose is missed, regulatory procedure states it can be taken as soon as possible. However, if the delay is more than two hours, the missed dose is omitted, and the schedule returns to its regular timing. Official guidance states that two doses should not be taken together.


Q: What does 'Galpent is for symptomatic relief' mean?

A: Clinical literature describes Galpent as being established for symptomatic treatment. This means its function is to alleviate or reduce the manifestation of a condition, such as angina, rather than attempting to cure the underlying disease process itself.

How should Galpent be stored and disposed of?

The storage and disposal of Galpent (Pentaerithrityl Tetranitrate) must adhere strictly to regulatory requirements to maintain product integrity and ensure safety.

Storage Conditions

Requirement Official Instruction
Temperature Store at room temperature in a cool, well-ventilated area.
Protection Keep in a dry place, protected from direct light, heat, and moisture.
Handling The container must be kept tightly closed and protected from physical shock or friction.

Disposal and Safety

Requirement Official Instruction
Child Safety Keep Galpent strictly out of the sight and reach of children.
Waste Dispose of unused or expired product as regulated hazardous waste; do not discard into the sewer or household drains.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Galpent found in:

A-Z Index: